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background: Although insulin offers a wide array of positive effects on the cardiovascular system, the benefit of exogenous insulin infusion on 
outcome after myocardial infarction (MI) remains controversial. Recently, rs7903146, a variant of transcription factor 7-like 2 (TCF7L2) gene has 
been associated with impaired insulin secretion and development of diabetes. In this context, our aim was to test if this polymorphism impacted 
endogenous insulin secretion and, consequently, the outcome after MI.
Methods: In non-diabetic patients (n=269) from a prospective cohort of ST elevation MI, we collected blood samples upon admission and day five. 
We assessed glycosylated hemoglobin, glucose, insulin, C-peptide, TNFα, and nitric oxide levels. The Homeostasis Model Assessment was used to 
estimate insulin secretion (HOMA2B) and insulin sensitivity (HOMA2S). We genotyped rs7903146 and grouped patients according to carrier status 
(CT+TT vs. CC). Flow-mediated dilation was performed after 30 days. Clinical follow-up consisted of trimestral visits until two years after MI. Primary 
endpoint was all-cause death within 30 days after MI and secondary endpoint was a composite of major cardiovascular events (MACE) consisting of 
fatal MI, non-fatal MI and cardiac sudden death.
results: T-allele carriers had lower HOMA2B at admission (112 vs 100, p<0,003) and D5 (105 vs 98, p<0,002), decreased C-peptide levels at D5 
(3.2 vs 3.8, p<0.001), higher HOMA2S at D1 (35 vs 42, p<0,02) and D5 (62 vs 73, p < 0,001) as well as a greater recovery (17 vs 23, p<0,001). 
Glycemia did not differ between groups. The change in TNFα levels was higher among carriers (5.9 vs 6.7, p<0,001). Decreased flow-mediated 
dilation (6.99 vs 7.74, p=0.001) and a reduced gain in nitric oxide levels (3.89 vs 4.93, p<0.001) was also detected. 30-day mortality was higher 
among T-allele carriers OR 6.04 (IC95% 1.21 – 30, p=0.028). Kaplan-Meier survival analysis showed no difference in MACE between groups within 
two years.
conclusion: In a prospective cohort of MI patients, we have shown that the rs7903146 polymorphism of the TCF7L2 gene is associated with 
decreased insulin secretion and endothelial function as well as increased short-term mortality.
